Advertisement
Canada markets close in 4 hours 16 minutes
  • S&P/TSX

    22,159.98
    -130.64 (-0.59%)
     
  • S&P 500

    5,182.69
    -5.01 (-0.10%)
     
  • DOW

    38,957.63
    +73.37 (+0.19%)
     
  • CAD/USD

    0.7288
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    78.87
    +0.49 (+0.63%)
     
  • Bitcoin CAD

    85,418.79
    -2,097.49 (-2.40%)
     
  • CMC Crypto 200

    1,318.26
    +23.59 (+1.82%)
     
  • GOLD FUTURES

    2,326.20
    +2.00 (+0.09%)
     
  • RUSSELL 2000

    2,053.07
    -11.58 (-0.56%)
     
  • 10-Yr Bond

    4.4860
    +0.0230 (+0.52%)
     
  • NASDAQ

    16,288.59
    -43.96 (-0.27%)
     
  • VOLATILITY

    13.21
    -0.02 (-0.15%)
     
  • FTSE

    8,353.88
    +40.21 (+0.48%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • CAD/EUR

    0.6777
    +0.0006 (+0.09%)
     

Company News For Jul 2, 2018

WF vs. BEN: Which Stock Is the Better Value Option?
  • Constellation Brands, Inc.’s STZ shares declined 5.8% after the company reported fiscal first quarter 2019 adjusted earnings of $2.20 per share, missing the Zacks Consensus Estimate of $2.42 per share

  • Shares of KB Home KBH jumped 7.3% after the company reported second-quarter fiscal 2018 earnings of $0.57 per share, surpassing the Zacks Consensus Estimate of $0.49 per share

  • Vertex Pharmaceuticals Incorporated’s VRTX shares surged 22.4% after the company announced that   Health Canada has approved its cystic fibrosis drug PrSYMDEKO

  • Shares of Fiat Chrysler Automobiles N.V. FCAU rose 1.3% on news of the company becoming a possible target of a takeover bid by Hyundai Motors


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Fiat Chrysler Automobiles N.V. (FCAU) : Free Stock Analysis Report
 
Constellation Brands Inc (STZ) : Free Stock Analysis Report
 
KB Home (KBH) : Free Stock Analysis Report
 
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research